MX2019012013A - Compuestos inhibidores de ask1 y usos de los mismos. - Google Patents
Compuestos inhibidores de ask1 y usos de los mismos.Info
- Publication number
- MX2019012013A MX2019012013A MX2019012013A MX2019012013A MX2019012013A MX 2019012013 A MX2019012013 A MX 2019012013A MX 2019012013 A MX2019012013 A MX 2019012013A MX 2019012013 A MX2019012013 A MX 2019012013A MX 2019012013 A MX2019012013 A MX 2019012013A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inhibitor compounds
- ask1 inhibitor
- methods
- prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Abstract
En el presente documento se describen compuestos, que incluyen sales, solvatos, metabolitos, profármacos farmacéuticamente aceptables de los mismos, métodos para preparar tales compuestos, composiciones farmacéuticas que comprenden tales compuestos y métodos para usar dichos compuestos para tratar la esteatohepatitis no alcohólica y otras enfermedades caracterizadas por la curación disfuncional del tejido y fibrosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026134 WO2018187506A1 (en) | 2017-04-05 | 2018-04-04 | Ask1 inhibitor compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012013A true MX2019012013A (es) | 2019-12-18 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012013A MX2019012013A (es) | 2017-04-05 | 2018-04-04 | Compuestos inhibidores de ask1 y usos de los mismos. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20210087167A1 (es) |
| EP (1) | EP3606519B1 (es) |
| JP (1) | JP7196093B2 (es) |
| KR (1) | KR102665145B1 (es) |
| CN (1) | CN110730661B (es) |
| AR (1) | AR111407A1 (es) |
| AU (1) | AU2018250217B2 (es) |
| BR (1) | BR112019021021A2 (es) |
| CA (1) | CA3059107A1 (es) |
| CL (1) | CL2019002810A1 (es) |
| CO (1) | CO2019011708A2 (es) |
| CR (1) | CR20190503A (es) |
| CU (1) | CU20190080A7 (es) |
| DK (1) | DK3606519T3 (es) |
| DO (1) | DOP2019000255A (es) |
| EA (1) | EA201992299A1 (es) |
| EC (1) | ECSP19078393A (es) |
| FI (1) | FI3606519T3 (es) |
| IL (1) | IL269711B (es) |
| JO (1) | JOP20190221A1 (es) |
| MA (1) | MA49047A (es) |
| MX (1) | MX2019012013A (es) |
| NI (1) | NI201900102A (es) |
| NZ (1) | NZ758345A (es) |
| PE (1) | PE20200009A1 (es) |
| PH (1) | PH12019502288A1 (es) |
| PT (1) | PT3606519T (es) |
| RU (1) | RU2019134679A (es) |
| SG (1) | SG11201909155VA (es) |
| TW (1) | TWI779022B (es) |
| WO (1) | WO2018187506A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| PL3621615T3 (pl) | 2017-05-12 | 2024-03-25 | Enanta Pharmaceuticals, Inc. | Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| JP7328254B2 (ja) | 2018-05-02 | 2023-08-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤を含むテトラゾール及びその使用方法 |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| JP2023514019A (ja) | 2019-12-27 | 2023-04-05 | ルピン・リミテッド | 置換三環式化合物 |
| MX2022013401A (es) | 2020-05-01 | 2022-11-14 | Pfizer | Compuestos de azalactama como inhibidores de hpk1. |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| TW202412761A (zh) * | 2022-07-20 | 2024-04-01 | 美商錫爾羅克醫療公司 | 以ａｓｋ１抑制劑治療器官疾病或病症的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| PT2531501E (pt) * | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Inibidores da cinase de regulação do sinal de apoptose 1 |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2012080735A1 (en) | 2010-12-16 | 2012-06-21 | Convergence Pharmaceuticals Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| CN106714841A (zh) * | 2014-09-24 | 2017-05-24 | 吉利德科学公司 | 治疗肝病的方法 |
| WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
| CA3050346C (en) | 2017-01-22 | 2020-07-14 | Fujian Cosunter Pharmaceutical Co., Ltd. | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| US11168095B2 (en) | 2017-02-07 | 2021-11-09 | Biogen Ma Inc. | ASK1 inhibiting agents |
| WO2018149284A1 (zh) | 2017-02-16 | 2018-08-23 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| WO2018183122A1 (en) | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| US20200308165A1 (en) | 2017-09-13 | 2020-10-01 | D.E. Shaw Research, Llc | Compounds as Ras Inhibitors and Use Thereof |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 BR BR112019021021A patent/BR112019021021A2/pt active Search and Examination
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active IP Right Grant
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en unknown
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 MX MX2019012013A patent/MX2019012013A/es unknown
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es unknown
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502288A1 (en) | Ask1 inhibitor compounds and uses thereof | |
| CR20220316A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| NZ761388A (en) | Methods of treatment for cystic fibrosis | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12020550341A1 (en) | Niraparib formulations | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| PH12017501652B1 (en) | Kv1.3 inhibitors and their medical application | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| JOP20180071B1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| UY37872A (es) | Derivados de difenilo y usos de los mismos | |
| MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
| ZA202005083B (en) | Solid forms of fasoracetam | |
| MX2021011081A (es) | Derivados de nicorandil. | |
| MX2020007062A (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| MX2018003289A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO. |